DSL(SH:603233) Huachuang Securities·2025-09-25 13:44Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 20.3 yuan [2][8]. Core Insights - The company demonstrated stable revenue growth with a 1.3% year-on-year increase in revenue to 13.52 billion yuan in the first half of 2025, while net profit attributable to shareholders rose by 21.4% to 800 million yuan [2][8]. - The growth in revenue is attributed to the performance of existing stores and contributions from newly opened and franchised stores, while profit growth is driven by revenue increase, improved management efficiency, and effective control of total operating costs [2][8]. - The company is focusing on high-quality development and expanding its presence in Southern China while dynamically optimizing its store network [2][8]. Financial Performance - In the first half of 2025, the company had a total of 16,833 stores, a 4.2% increase year-on-year, with a decrease in direct-operated stores by 3.7% and a 20.2% increase in franchised stores [2][8]. - The retail pharmacy business generated revenue of 11 billion yuan, a slight decline of 0.5% year-on-year, while the gross margin improved by 0.4 percentage points to 37.6% [2][8]. - The company’s net profit margin increased to 6.3%, up by 1.0 percentage points year-on-year, indicating effective cost control measures [2][8]. Future Projections - The report adjusts the company's net profit forecasts for 2025-2027 to 1.16 billion yuan, 1.33 billion yuan, and 1.53 billion yuan, respectively, with year-on-year growth rates of 27%, 15%, and 15% [2][8]. - The projected earnings per share (EPS) for 2025 is 1.02 yuan, with a price-to-earnings (P/E) ratio of 20 times [2][8].